European Journal of Vascular & Endovascular Surgery
Volume 35, Issue 6 , Pages 701-708 , June 2008

Management of Hypertension in Peripheral Arterial Disease: Does the Choice of Drugs Matter?

  • D.R.J. Singer

      Affiliations

    • Clinical Sciences Research Institute, Warwick Medical School, University of Warwick, United Kingdom
    • University Hospital, Coventry CV2 2DX, United Kingdom
    • Corresponding Author InformationCorresponding author. D. R. J. Singer, Professor of Clinical Pharmacology & Therapeutics, Clinical Sciences Research Institute, Warwick Medical School, University of Warwick, University Hospital, Clifford Bridge Road, Coventry CV2 2DX, United Kingdom.
    • ,
  • A. Kite

      Affiliations

    • University Hospital, Coventry CV2 2DX, United Kingdom

,Accepted 15 January 2008.

References 

  1. Lip GY, Makin AJ. Treatment of hypertension in peripheral arterial disease. Cochrane Database Syst Rev. 2003;(4):CD003075
  2. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997;157:2413–2446
  3. Feringa HH, van Waning VH, Bax JJ, Elhendy A, Boersma E, Schouten O, et al. Cardioprotective medication is associated with improved survival in patients with peripheral arterial disease. J Am Coll Cardiol. 2006;47:1182–1187
  4. Feringa HH, Karagiannis SE, Chonchol M, Vidakovic R, Noordzij PG, Elhendy A, et al. Lower progression rate of end-stage renal disease in patients with peripheral arterial disease using statins or angiotensin converting enzyme inhibitors. J Am Soc Nephrol. 2007;18:1872–1879
  5. Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286:1317–1324
  6. Ostchega Y, Paulose-Ram R, Dillon CF, Gu Q, Hughes JP. Prevalence of peripheral arterial disease and risk factors in persons aged 60 and older: data from the National Health and Nutrition Examination Survey 1999–2004. J Am Geriatr Soc. 2007;55:583–589
  7. Meijer WT, Grobbee DE, Hunink MG, Hofman A, Hoes AW. Determinants of peripheral arterial disease in the elderly: the Rotterdam study. Arch Intern Med. 2000;160:2934–2938
  8. Kullo IJ, Bailey KR, Kardiad SLR, Mosley TH, Boerwinkle E, Turner ST. Ethnic differences in peripheral arterial disease in the NHLBI Genetic Epidemiology Network of Arteriopathy (GENOA) study. Vasc Med. 2003;8:237–242
  9. Missouris CG, Buckenham T, Cappuccio FP, MacGregor GA. Renal artery stenosis: a common and important problem in patients with peripheral vascular disease. Am J Med. 1994;96:10–14
  10. Wachtell K, Ibsen H, Olsen MH, Laybourn C, Christoffersen JK, Nørgaard H, et al. Prevalence of renal artery stenosis in patients with peripheral vascular disease and hypertension. J Hum Hypertens. 1996;10:83–85
  11. Ozkan U, Oguzkurt L, Tercan F, Nursal TZ. The prevalence and clinical predictors of incidental atherosclerotic renal artery stenosis. Eur J Radiol. 2007 Dec 3;[epub ahead of print]
  12. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002 May 15;287(19):2570–2581
  13. Leertouwer TC, Pattynama PM, van den Berg-Huysmans A. Incidental renal artery stenosis in peripheral vascular disease: a case for treatment?. Kidney Int. 2001;59:1480–1483
  14. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med. 2001;344:3–10
  15. Cook NR, Cutler JA, Obarzanek E, Buring JE, Rexrode KM, Kumanyika SK, et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ. 2007;334:885
  16. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, et al. Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335:827–838
  17. Pepine CJ, Kowey PR, Kupfer S, Kolloch RE, Benetos A, Mancia G, et al. INVEST investigators. Predictors of adverse outcome among patients with hypertension and coronary artery disease. J Am Coll Cardiol. 2006;47:547–551
  18. Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Intern Med. 1991;151:1769–1776
  19. Solomon SA, Ramsay LE, Yeo WW, Parnell L, Morris-Jones W. Beta blockade and intermittent claudication: placebo controlled trial of atenolol and nifedipine and their combination. BMJ. 1991;303:1100–1104
  20. Ubbink DT, Verhaar EE, Lie HK, Legemate DA. Effect of beta-blockers on peripheral skin microcirculation in hypertension and peripheral vascular disease. J Vasc Surg. 2003;38:535–540
  21. Poldermans D, Boersma E, Bax JJ, Thomson IR, Paelinck B, van de Ven LL, et al. Bisoprolol reduces cardiac death and myocardial infarction in high-risk patients as long as 2 years after successful major vascular surgery. Eur Heart J. 2001;22:1353–1358
  22. Narins CR, Zareba W, Moss AJ, Marder VJ, Ridker PM, Krone RJ, et al. Relationship between intermittent claudication, inflammation, thrombosis, and recurrent cardiac events among survivors of myocardial infarction. Arch Intern Med. 2004;164:440–446
  23. Toda N. Vasodilating beta-adrenoceptor blockers as cardiovascular therapeutics. Pharmacol Ther. 2003;100:215–234
  24. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, et al. British Hypertension Society Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens. 2004;18:139–185
  25. CG34. Hypertension: management in adults in primary care: pharmacological update. British Hypertension Society and National Institute for Healthcare Excellence; July 2007;Available from: www.nice.org.uk
  26. Zanchetti A, Julius S, Kjeldsen S, McInnes GT, Hua T, Weber M, et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial. J Hypertens. 2006;24(11):2163–2168
  27. Mehler PS, Coll JR, Estacio R, Esler A, Schrier RW, Hiatt WR. Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. Circulation. 2003;107:753–756
  28. Ostergren J, Sleight P, Dagenais G, Danisa K, Bosch J, Qilong Y, et al. HOPE study investigators. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J. 2004;25:17–24
  29. Hunyady L, Catt KJ. Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol Endocrinol. 2006;20:953–970
  30. van de Ven PJ, Beutler JJ, Kaatee R, Beek FJ, Mali WP, Koomans HA. Angiotensin converting enzyme inhibitor-induced renal dysfunction in atherosclerotic renovascular disease. Kidney Int. 1998;53:986–993
  31. Dominiczak A, Isles C, Gillen G, Brown JJ. Angiotensin converting enzyme inhibition and renal insufficiency in patients with bilateral renovascular disease. J Hum Hypertens. 1988;2:53–56
  32. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or hypertension treatment (INSIGHT). Lancet. 2000;356:366–372
  33. Williams G, Donaldson RM. Nifedipine and nocturia. Lancet. 1986;29(1):738
  34. Scottish Inter-Collegiate Guidelines Network . Diagnosis and management of peripheral arterial disease. SIGN guideline 89; October 2006;
  35. Management of type 2 diabetes. Renal disease – prevention and early management. NICE Guidelines; Feb 2002;Available from: www.nice.org.uk
  36. Hadorn DC, Baker D, Hodges JS, Hicks N. Rating the quality of evidence for clinical practice guidelines. J Clin Epidemiol. 1996;49:749–754
  37. Powell JT. Intermittent claudication: a plea for guidelines for medical management. Eur J Vasc Endovasc Surg. 2007;33:451–452
  38. Khan S, Flather M, Mister R, Delahunty N, Fowkes G, Bradbury A, et al. Characteristics and treatments of patients with peripheral arterial disease referred to UK vascular clinics: results of a prospective registry. Eur J Vasc Endovasc Surg. 2007;33:442–450

PII: S1078-5884(08)00047-6

doi: 10.1016/j.ejvs.2008.01.007

European Journal of Vascular & Endovascular Surgery
Volume 35, Issue 6 , Pages 701-708 , June 2008

Article Tools

* Image Usage & Resolution